## The Medical Letter® On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

IN THIS ISSUE (starts on next page)

In Brief: Transdermal Rotigotine (Neupro) ...... p 68

## Important Copyright Message

The Medical Letter<sup>®</sup> publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769

FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call: 800-211-2769

# The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 54 (Issue 1397) August 20, 2012

www.medicalletter.org

#### **IN BRIEF**

### **Transdermal Rotigotine** (Neupro)

A patch formulation of the non-ergot dopamine agonist rotigotine (*Neupro* – UCB) has returned to the US market after a 4-year absence. Originally approved by the FDA in 2007 for treatment of early Parkinson's disease,<sup>1</sup> it was withdrawn in 2008 because of crystallization of the drug in the patch, which could have led to under-dosing. The new patch has somewhat broader indications than the old one; it is approved for use in any stage of Parkinson's disease (PD) and also for moderate-to-severe restless legs syndrome (RLS).

1. Transdermal rotigotine (Neupro) for Parkinson's disease. Med Lett Drugs Ther 2007; 49:69.

#### Table 1. Non-Ergot Dopamine Agonists for PD and RLS

Drug	Usual Dosage for PD	Usual Dosage for RLS	Cost <sup>1</sup>
Patch			
Rotigotine <i>Neupro</i> (UCB)	2-8 mg/24 hrs patch once/d	1-3 mg/24 hrs patch once/d	\$127.50 <sup>2</sup>
Oral			
Pramipexole – generic <i>Mirapex</i> (Boehringer Ingelheir extended-release	0	0.125-0.5 mg <sup>3</sup>	25.89 356.62
Mirapex ER	1.5-4.5 mg once/d	not approved	337.43
Ropinirole – generic <i>Requip</i> (GSK) extended-release	3-8 mg tid	0.25-4 mg <sup>3</sup>	42.78 277.83
generic <i>Requip XL</i>	8-24 mg once/d	not approved	193.87 228.18

 Cost of 30 days' treatment at the lowest usual dose for treatment of PD, according to PricePointRx<sup>™</sup>. Reprinted with permission by FDB. All rights reserved. ©2012. http://www.firstdatabank.com/support/drug-pricing-policy.aspx. Accessed August 13, 2012. Actual retail prices may be higher.

 Thirty 1, 2 or 3 mg/24 hour patches cost \$127.50. Thirty 4, 6, 8 mg/24 hour patches cost \$375.

3. Once daily 2-3 hours before bedtime.

#### The Medical Letter® On Drugs and Therapeutics

EDITOR IN CHIEF: Mark Abramowicz, M.D. EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D. ASSISTANT EDITORS, DRUG INFORMATION: Susan M. Daron, Pharm.D., Corinne E. Zanone, Pharm.D. CONSULTING EDITORS: Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D. CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School Eric J. Epstein, M.D., Albert Einstein College of Medicine Jane P. Gagliardi, M.D., M.H.S., F.A.C.P Duke University School of Medicine Jules Hirsch, M.D., Rockefeller University David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre Richard B. Kim, M.D., University of Western Ontario Hans Meinertz, M.D., University Hospital, Copenhagen Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba

Neal H. Steigbigel, M.D., New York University School of Medicine Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weil Medical College of Cornell University SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard

ASSOCIATE EDITOR: Cynthia Macapagal Covey EDITORIAL FELLOW: Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School MANAGING EDITOR: Susie Wong

ASSISTANT MANAGING EDITOR: Liz Donohue PRODUCTION COORDINATOR: Cheryl Brown

EXECUTIVE DIRECTOR OF SALES: Gene Carbona FULFILLMENT & SYSTEMS MANAGER: Cristine Romatowski **DIRECTOR OF MARKETING COMMUNICATIONS: Joanne F. Valentino** VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

#### Subscription Services

Mailing Address: The Medical Letter, Inc. 145 Huguenot St. Ste. 312 New Rochelle, NY 10801-7537

**Customer Service:** Call: 800-211-2769 or 914-235-0500 Fax: 914-632-1733 Web Site: www.medicalletter.org

E-mail: custserv@medicalletter.org Permissions:

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Copyright 2012. ISSN 1523-2859

1 year - \$98; 2 years - \$189; 3 years - \$279. \$49.00 per year for students, interns, residents and fellows in the US and Canada.

#### E-mail site license inquiries to:

Subscriptions (US):

info@medicalletter.org or call 800-211-2769 x315. Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.

